1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow FACT Complex-targeting Curaxin CBL0137: new trials by email Literature Review of FACT Complex-targeting Curaxin CBL0137 trials Research Report on FACT Complex-targeting Curaxin CBL0137
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Diffuse Midline Glioma, H3 K27-Altered, Metastatic Malignant Neoplasm in the Central Nervous System | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 63 | 2022-01-28 | 2026-09-11 |
| CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma FACT Complex-targeting Curaxin CBL0137 - Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity | Phase 1 | Terminated | Roswell Park Cancer Institute | 7 | 2019-07-01 | 2024-03-27 |
Diffuse Intrinsic Pontine Glioma (1) · Lymphoma (1)
Children's Oncology Group (1) · Roswell Park Cancer Institute (1)
United States (2) · Australia (1)
David S Ziegler (1) · Joseph Skitzki (1)
UM1CA228823 (1)